Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on Frontiers in Genetics
One of our clients FDA-National Center for Toxicological Research (NCTR) has published the results of a study using STAMTM model on Frontiers in Genetics. Title: “Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis” By using STAMTM model (NASH-HCC model), they demonstrated that NASH-related HCC is characterized by progressive accumulation of gene…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on Experimental Animals
We announced that the results of a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Experimental Animals: Title: “Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM mice” They reported that the results of analysis of…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on Journal of Cellular and Molecular Medicine
We announced that the results of a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Journal of Cellular and Molecular Medicine by Pharmaxis Ltd.: Title: “The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis” Lysyl oxidases regulate many biological processes including…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on Scientific Reports
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Scientific Reports: Title: “Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan” Telmisartan is a potential treatment for NASH/NAFLD due to its ability to improve inflammation and…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on NPJ Precision Oncology
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in NPJ Precision Oncology by Genentech, Inc.: Title: “Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology” This study reported that treatment of TGF-β neutralizing antibody in the…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on Cellular and Molecular Gastroenterology and Hepatology
We announced that the results of the study in the STAM™ mouse model of NASH has been published in Cellular and Molecular Gastroenterology and Hepatology by Kawasaki Medical School: Title: “Dipeptidyl Peptidase 4 inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice” The authors demonstrated that Sitagliptin, a DPP-4 inhibitor, attenuated development of…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on Glycoconjugate Journal
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Glycoconjugate Journal by Shionogi & Co., Ltd.: Title: “Identification of unique glycoisoforms of vitamin D-binding protein and haptoglobin as biomarker candidates in hepatocarcinogenesis of STAM mice” This study reports unique glycoisoforms as candidates…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on Liver Cancer
We announced that a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Liver Cancer by Kurume University: Title: “Effects of a DPP4 inhibitor on progression of NASH-related HCC and the p62/Keap1/Nrf2-Pentose phosphate pathway in a mouse model” The results of the study demonstrated in the…
2025.02.02
One of our clients published preclinical data on NASH-fibrosis on PLoS One
We announced that a study in the STAM mouse model of NASH performed by SMC Laboratories Inc. has been published in PLoS One by Gemphire Therapeutics: Title: “Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH” The results of the study demonstrated Gemcabene in the STAM™ model showed a reduction…
2025.02.02
One of our clients published preclinical data on the FASEB Journa
One of our clients FDA-National Center for Toxicological Research (NCTR) has published the results of a study using STAMTM model on The FASEB Journal. Title: “Epigenetically mediated inhibition of S-adenosylhomocysteine hydrolase and the associated dysregulation of 1-carbon metabolism in nonalcoholic steatohepatitis and hepatocellular carcinoma” By using STAMTM model (NASH-HCC model), they demonstrated that advanced…
We can help you advance your research.